Rachael Liu

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus et al. · New England Journal of Medicine · 2017 · 764 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors et al. · The Lancet Haematology · 2021 · 160 citations

Medicine, Oncology, Pharmacotherapy +14

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

David J. Straus, Monika Długosz‐Danecka, Sergey Alekseev et al. · Blood · 2020 · 112 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Safety, Tolerability and Pharmacokinetics of Doravirine, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, after Single and Multiple doses in Healthy Subjects

Matt S. Anderson, Jocelyn Gilmartin, Caroline Cilissen et al. · Antiviral Therapy · 2014 · 78 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

Andrew M. Evens, Joseph M. Connors, Anas Younes et al. · Haematologica · 2021 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +13